City Therapeutics to Present at Upcoming November Investor Conferences
City Therapeutics (Nasdaq: CTY) management will participate in two investor conferences in November, with appearances in New York and London.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
City Therapeutics (Nasdaq: CTY) management will participate in two investor conferences in November, with appearances in New York and London.
The Stifel 2026 Healthcare Conference fireside chat is November 10 at 10:00 a.m. ET. The Jefferies Global Healthcare Conference presentation is November 16 at 1:00 p.m. GMT. Live webcasts will be available through the company's investor website, with replays available for approximately 90 days.
Details
News Market Reaction – CTY
On Nov 3, the day this news came out, CTY closed 8.57% below the previous close. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner recorded 21 alerts for this stock that day.
Data tracked by StockTitan Argus for the Nov 3 session.
Key Terms
rna interference technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced that management will participate in the following investor conferences in November.
Stifel 2026 Healthcare Conference
Fireside Chat: Tuesday, November 10, 2026, at 10:00 a.m. ET
Location: New York, New York
Jefferies Global Healthcare Conference in London
Presentation: Monday, November 16, 2026, at 1:00 p.m. GMT
Location: London, England
Live webcasts of the fireside chat and presentation will be available on the “News & Events” page within the Investors section of the City Therapeutics’ website at investors.citytx.com. A replay of the webcasts will be available for approximately 90 days.
About City Therapeutics
City Therapeutics is a clinical-stage biotechnology company engineering the next generation of RNA interference (RNAi) therapeutics, with the aim of delivering meaningful and durable benefits for patients in need. City’s lead development programs are CITY-FXI for thromboembolic diseases, CITY-RBP4 for Stargardt disease and other retinal diseases, and CITY-TFR2 for anemia associated with chronic diseases. The City Platform is the engine behind every therapeutic the company develops and integrates deep expertise in trigger engineering, including proprietary cityRNA triggers designed to address limitations of conventional RNAi approaches, tissue-selective delivery, and genetics-driven target selection. For more information, visit www.citytx.com and follow us on LinkedIn, X, and Bluesky.
Media Contact:
Katie Engleman, 1AB
katie@1abmedia.com
Investor Contact:
Stephanie Ascher, Precision AQ
Stephanie.Ascher@precisionaq.com
